Skip to main content

Table 2 Numbers of women randomized, follow-up periods and breast cancers detected (including in situ lesions)

From: Future possibilities in the prevention of breast cancer: Breast cancer prevention trials

   

Cancers

Trial

Total randomized

Median follow up (months)

Total

Tamoxifen/raloxifene

Placebo

OR

RMH [5*]

2 471

70

70

34

36

0.94

NSABP [3*]

13 388

57

368

124

244

0.51

Italian [6*]

5 408

46

41

19 (11)†

22(19)‡

0.91

IBIS*

6 037

30

88

-*

-*

-*

MORE [7*]

7 705

40

54

22/2‡

32

0.35

  1. *As of 1 December 1999 (ongoing and still blinded). †Tamoxifen >1 year. ‡2:1 ratio of raloxifene:placebo in MORE study.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us